



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

January 26, 2024

Tiewei Song  
Chief Executive Officer  
BIMI International Medical Inc.  
9th Floor, Building 2  
Chongqing Corporation Avenue  
Yuzhong District, Chongqing,  
P. R. China, 400010

**Re: BIMI International Medical Inc.**  
**Form 10-K for the Fiscal Year Ended December 31, 2022**  
**Filed May 4, 2023**  
**Correspondence Filed April 24, 2023**  
**File No. 001-34890**

Dear Tiewei Song:

We issued comments to you on the above captioned filings on July 17, 2023. As of the date of this letter, these comments remain outstanding and unresolved. We expect you to provide a complete, substantive response to these comments by February 9, 2024.

If you do not respond, we will, consistent with our obligations under the federal securities laws, decide how we will seek to resolve material outstanding comments and complete our review of your filings and your disclosure. Among other things, we may decide to release publicly, through the agency's EDGAR system, all correspondence, including this letter, relating to the review of your filings, consistent with the staff's decision to publicly release comment and response letters relating to disclosure filings it has reviewed.

Please contact Nasreen Mohammed at 202-551-3773 or Adam Phippen at 202-551-3336 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Trade & Services

cc: Pang Zhang-Whitaker